Office of Device Evaluation (D.H., M.E.T., M.E.), Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland; Boston Foundation for Sight (D.S.J.), Needham, Massachusetts; Department of Ophthalmology and Visual Sciences (L.S.-F., T.S.), Case Western Reserve University, Cleveland, Ohio; Division of Ophthalmology (T.S.), MetroHealth Medical Center, Cleveland, Ohio; Department of Ophthalmology (D.D.), UPMC/University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania; American Optometric Association (M.R.D.), St. Louis, Missouri; and Department of Ophthalmology and Visual Sciences (B.H.J.), University of Maryland School of Medicine, Baltimore, Maryland.
Address correspondence to Malvina Eydelman, M.D., 10903 New Hampshire Ave, Silver Spring, MD 20993; e-mail: email@example.com
Participant and nonfederal authors' travel was provided by the four cosponsoring organizations. L. Szczotka-Flynn: Pending grant support from Alcon and Johnson & Johnson Vision Care. D. Dhaliwal: Grant Support from 11 Therapeutics, Avedro, and AMO. The remaining authors have no funding or conflicts of interest to disclose.
The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services (DHHS).
Accepted September 02, 2015